4F-MPH 30 MG kúlur (4-flúormetýlfenidat)
4F-MPH 30 MG kúlur (4-flúormetýlfenidat) Verðbil: €18.95 til €549.95
Til baka í vörur
1cP-MiPLA 200 MCG þynnur
1cP-MiPLA 200 MCG þynnur Verðbil: €6.50 til €399.95

IDRA-21 10 MG kúlur

IDRA-21 Pellets properties

Samheiti 7-klór-3-metýl-3,4-díhýdró-2H-1,2,4-bensótíadíasín 1,1-díoxíð
CAS Fjöldi : 22503-72-6
Formúla C8H9ClN2O2S
Mólmassi : 232,6 g/mól
Hreinleiki : >97%

Verðbil: €13.50 til €398.58

* Upplýsingarnar á þessari síðu eru samantekt og eru ekki ætlaðar til að ná yfir allar tiltækar upplýsingar um þetta lyf. Þær fjalla ekki um alla mögulega notkun, leiðbeiningar, varúðarráðstafanir, milliverkanir lyfja eða aukaverkanir og koma ekki í stað sérfræðiþekkingar og mats heilbrigðisstarfsmanns.

IDRA-21 10 MG Pellets – Scientific Description & User Manual

Vörulýsing

IDRA-21 (10 mg kúlur)  is a potential  AMPA receptor potentiator  belonging to the class of  nootropic and neuroprotective research chemicals . It works by enhancing glutamate-induced signaling in the brain, which may lead to improved cognitive function, neuroplasticity, and potentially neurorecovery.

Þessar kúlur eru  highly pure (≥98%) , standardized dosed and intended solely for  scientific research and preclinical studies .


Uses & Applications

IDRA-21 is being studied for its possible effects on:

  1. Cognitive Enhancement  – ​​May increase alertness, learning ability, and memory consolidation.

  2. Neuroprotection  – Potential protective effect in neurodegenerative diseases (e.g. Alzheimer’s, stroke).

  3. Neurological Recovery  – May Promote Synaptic Plasticity After Brain Injury.

  4. Scientific Research  – Study of AMPA receptor modulation and glutamate signaling.

⚠ Not approved for human or veterinary use – For in vitro and controlled preclinical studies only.


Dosage & Safety Guidelines

  • Investigational dosage (in vitro/preclinical):  5–20 mg/kg  (depending on model).

  • Pellet Solution:  Can be dissolved in  distilled water or DMSO  for experiments.

  • Stjórnsýsla:  Orally (animal models) or directly in cell cultures.

  • Frequency:  Single dose for acute effect; long-term studies require careful monitoring.

🚨 NB:

  • No human application  – No safety data for human use.

  • High doses may cause neuroexcitotoxicity.

  • Avoid combination with other glutamate modulators.


Ókostir og áhætta

  • Overstimulation of neurons  (risk of excitotoxicity in case of overdose).

  • Möguleg kvíði eða æsingur  in susceptible models.

  • Takmarkaðar langtímaupplýsingar  on tolerance and adverse effects.

  • Not suitable for chronic use  without extensive toxicity studies.


Algengar spurningar (FAQs)

1. Is IDRA-21 legal in the Netherlands?

Yes, but only for  vísindarannsóknir . It doesn’t fall under the Opium Act, but it’s also not approved as a medicine.

2. How exactly does IDRA-21 work?

It  enhances the AMPA receptor response , making glutamate signaling longer and more intense. This can lead to improved synaptic communication.

3. Can IDRA-21 be compared to other nootropics?

It has a unique mechanism of action, but  similar targets as racetams or ampakines  (e.g. Sunifiram).

4. Are there any known interactions?

  • NMDA antagonists  (e.g. memantine) – Potentially adverse effects.

  • GABAergic agents  (e.g., benzodiazepines) – May reduce anxiolytic effects.


Rannsóknarskýrsla og gæðaeftirlit

  • HPLC analysis:  ≥98% purity .

  • No detectable heavy metals or solvent residues .

  • Homogeneous pellet formulation  for consistent dosing.

  • Batch certification  available for research institutions.


Ráðlagðar rannsóknarsviðsmyndir

  1. Cognitive studies  – Effects on memory and learning in animal models.

  2. Neuroprotective research  – Potential role in ischemic injury (stroke models).

  3. Raflífeðlisfræði  – AMPA receptor response measurements in neuronal cultures.

🔬 For controlled laboratory use only – No recreational use!